Silberstein, 2020 - Google Patents
Is PNC-27 and PNC-28 the Best way to cure Cancer?Silberstein, 2020
View PDF- Document ID
- 6934890722561927640
- Author
- Silberstein M
- Publication year
- Publication venue
- The Science Journal of the Lander College of Arts and Sciences
External Links
Snippet
Immunotherapeutic agents have been researched for many decades as an alternative treatment for cancer. Current research demonstrates that immunotherapy is safer than radiotherapy or chemotherapy. This is attributed to immunotherapy's mechanism of utilizing …
- 201000011510 cancer 0 title abstract description 112
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mondini et al. | Radiotherapy–immunotherapy combinations–perspectives and challenges | |
| Peuget et al. | Translating p53-based therapies for cancer into the clinic | |
| Kim et al. | Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation | |
| Lun et al. | Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin | |
| Ringer et al. | The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells | |
| Tian et al. | Radioactive 125I seed inhibits the cell growth, migration, and invasion of nasopharyngeal carcinoma by triggering DNA damage and inactivating VEGF-A/ERK signaling | |
| US20230416721A1 (en) | Combination therapeutics using tumor treating fields (ttfields) | |
| US20240366736A1 (en) | Method for managing pain | |
| Woo et al. | Rapamycin promotes ROS-mediated cell death via functional inhibition of xCT expression in melanoma under γ-irradiation | |
| Zhang et al. | APE1 promotes non-homologous end joining by initiating DNA double-strand break formation and decreasing ubiquitination of artemis following oxidative genotoxic stress | |
| Veeranki et al. | Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma | |
| Pascual-Serra et al. | p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models | |
| Nickson et al. | USP9X is required to maintain cell survival in response to high-LET radiation | |
| Aubry et al. | Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses | |
| Zhu et al. | Zoledronic acid regulates autophagy and induces apoptosis in colon cancer cell line CT26 | |
| Zhang et al. | Angioplasty induces epigenomic remodeling in injured arteries | |
| Tang et al. | MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies | |
| Corona et al. | Current experimental therapies for atypical and malignant meningiomas | |
| Silberstein | Is PNC-27 and PNC-28 the Best way to cure Cancer? | |
| Qiu et al. | TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis | |
| Zhu et al. | Radiotherapy suppresses bone cancer pain through inhibiting activation of cAMP signaling in rat dorsal root ganglion and spinal cord | |
| JP2020503322A (en) | Reduced chemotherapy damage and increased cancer mortality by incorporating low-dose radiation | |
| Arienti et al. | Efficacy of Different Sequences of Radio‐and Chemotherapy in Experimental Models of Human Melanoma | |
| Lim et al. | Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation | |
| US20240001142A1 (en) | Induction by low dose radiation of cancer cell targets for cell-based or small molecule therapy |